You are here: Industry Insights > Semaglutide

News List

Popular APIs of the Year at Pharmasources.com PharmaSources
December 10, 2024
What are the APIs that caught the highest attention in the year at PharmaSources.com？
The Rapidly Expanding Global Weight Loss Market and the Role of Chinese Innovations PharmaSources/ChatGPT
August 28, 2024
The trend highlights China’s growing influence in the global pharmaceutical landscape and its increasing role in advancing global health solutions.
Glucagon-like peptide-1 (GLP-1) Receptor Agonist Semaglutide in an Oleogel Formulation Using the BrainDos™ Technology Significantly Increases Drug Delivery into Cells PharmaSources
May 09, 2024
MetP Pharma AG, leveraging the proprietary nose-to-brain drug delivery technology BrainDos™ in internal and external product development and manufacturing programs.
Why the unit price gap of the weight loss drug GLP-1 is nearly ten times? Lao Xue/PharmaSources
May 22, 2023
GLP-1 drugs can be used for weight loss. Why the unit price difference is nearly ten times?
NICE approves Wegovy™ (semaglutide) for obesity EuropeanPharmaceuticalReview
February 11, 2022
New draft guidance means thousands of obese Brits could benefit from Novo Nordisk’s Wegovy™ (semaglutide), a drug shown to improve weight loss.
New management: Promising drug for people living with obesity pharmatimes
February 08, 2022
NICE recommends appetite suppressing drug which can reduce a patient’s by more than 10%.
Investigational 2 mg Dose of Ozempic (semaglutide) Injection Demonstrates Superior Reductions in Blood Sugar vs Ozempic 1 mg in Adults With Type 2 Diabetes in a Phase 3 Trial firstwordpharma
June 28, 2021
Novo Nordisk today presented data showing that an investigational 2 mg dose of Ozempic® (semaglutide) injection provided statistically significant and superior reductions in blood sugar (A1C) compared with Ozempic®1 mg.
FDA Approves Wegovy (semaglutide) to Treat Adults with Obesity drugs
June 07, 2021
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the new drug application (NDA) for Wegovy™ (semaglutide) injection 2.4 mg, the first-and-only prescription weight-loss medication with once-weekly dosing.
FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014 fda.gov
June 07, 2021
Today, the U.S. Food and Drug Administration approved Wegovy (semaglutide) injection for chronic weight management in adults with obesity or overweight with at least one weight-related condition for use in addition to a reduced calorie diet and increased
Novo Nordisk’s weight loss drug semaglutide found to improve wellbeing pharmatimes
May 14, 2021
New results from a Phase IIIa study have demonstrated that Novo Nordisk’s weight loss drug semaglutide improved physical function and wellbeing among people with obesity.

Previous page 1 2 3 4 Next page